Clearside Biomedical Enters into Non-Dilutive Financing Settlement with HealthCare Royalty Companions for as much as $65 Million
Clearside Biomedical, Inc. – Transaction Helps Development of CLS-AX Scientific Program – ALPHARETTA, Ga., Aug. 08, 2022 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical firm revolutionizing the supply of therapies to the again of the attention by means of the suprachoroidal house (SCS®), introduced as we speak it has entered right into a […]
Continue Reading